1 |
Ito F, Chang AE (2013). Cancer immunotherapy: current status and future directions. Surg Oncol Clin N Am, 22, 765-83.
DOI
|
2 |
Janelsins MC, Tejani MA, Kamen C, et al (2013). Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacother, 14, 757-66.
DOI
|
3 |
Keat CH, Ghani NA (2013). Cost-effectiveness analysis of granisetron-based versus standard antiemetic regimens in low-emetogenic chemotherapy: a hospital-based perspective from Malaysia. Asian Pac J Cancer Prev, 14, 7701-6.
과학기술학회마을
DOI
ScienceOn
|
4 |
Li F, Zhao C, Wang L (2014). Molecular-targeted agents combination therapy for cancer: developments and potentials. Int J Cancer, 134, 1257-69.
DOI
|
5 |
McIntyre RS, Cha DS, Kim RD, et al (2013). A review of FDAapproved treatment options in bipolar depression. CNS Spectr, 18, 4-20.
|
6 |
Mizukami N, Yamauchi M, Koike K, et al (2013). Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. J Pain Symptom Manage, [Epub ahead of print].
|
7 |
Moore MA, Sangrajrang S, Bray F (2014). Asian cancer registry forum 2014 - regional cooperation for cancer registration: priorities and challenges. Asian Pac J Cancer Prev, 15, 1891-4.
과학기술학회마을
DOI
|
8 |
Navari RM, Einhorn LH, Passik SD, et al (2005). A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer, 13, 529-34.
DOI
ScienceOn
|
9 |
Navari RM, Einhorn LH, Loehrer PJ Sr, et al (2007). A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer, 15, 1285-91.
DOI
|
10 |
Navari RM, Gray SE, Kerr AC (2011). Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol, 9, 188-95.
DOI
|
11 |
Navari RM, Nagy CK, Gray SE (2013). The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer, 21, 1655-63.
DOI
|
12 |
Navari RM (2014). Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. Eur J Pharmacol, 722, 180-6.
DOI
|
13 |
NCCN clinical Practice guidelines in oncology- Antiemesis Version I, 2014. http://www.nccn.org/professionals/ physician_gls/f_guidelines.asp#supportive.
|
14 |
Pirl WF, Roth AJ (2000). Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report. Psychooncol, 9, 84-7.
DOI
|
15 |
Passik SD, Lundberg J, Kirsh KL, et al (2002). A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage, 23, 526-32.
DOI
|
16 |
Passik SD, Kirsh KL, Theobald DE, et al (2003). A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manage, 25, 485-8.
DOI
|
17 |
Daher M (2012). Cultural beliefs and values in cancer patients. Ann Oncol, 23, 66-9.
DOI
|
18 |
Brafford MV, Glode A (2014). Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol, 5, 24-9.
|
19 |
Copier J, Bodman-Smith M, Dalgleish A (2011). Current status and future applications of cellular therapies for cancer. Immunotherapy, 3, 507-16.
DOI
|
20 |
Chen W, Zheng R, Zhang S, et al (2014). Annual report on status of cancer in China, 2010. Chin J Cancer Res, 26, 48-58.
|
21 |
Flank J, Sung L, Dvorak CC, Spettigue W, Dupuis LL (2014). The Safety of Olanzapine in Young Children: A Systematic Review and Meta-Analysis. Drug Saf . [Epub ahead of print]
|
22 |
Hesketh PJ, Grunberg SM, Gralla RJ, et al (2003). The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol, 21, 4112-9.
DOI
ScienceOn
|
23 |
Hassan BA, Yusoff ZB (2010). Negative impact of chemotherapy on breast cancer patients QOL - utility of antiemetic treatment guidelines and the role of race. Asian Pac J Cancer Prev, 11, 1523-7.
|
24 |
Hocking CM, Kichenadasse G. (2014). Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer, 22, 1143-51.
DOI
|
25 |
Sliwkowski MX, Mellman I (2013). Antibody therapeutics in cancer. Science, 341, 1192-8.
DOI
|
26 |
Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al (2003). Cancer. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer, 97, 3090-8.
DOI
ScienceOn
|
27 |
Passik SD, Navari RM, Jung SH, et al (2004). A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest, 22, 383-8.
DOI
|
28 |
Roila F, Herrstedt J, Aapro M, et al (2010). Guideline update for MASCC and ESMO in the prevention of chemotherapyand radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol, 21, 232-43.
DOI
|
29 |
Siegel R, Ma J, Zou Z, et al (2014). Cancer statistics, 2014. CA Cancer J Clin, 64, 9-29.
DOI
|
30 |
Tan L, Liu J, Liu X, et al (2009). Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res, 28, 131.
DOI
|
31 |
Uchino J, Hirano R, Tashiro N, et al (2012). Efficacy of aprepitant in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy. Asian Pac J Cancer Prev, 13, 4187-90.
과학기술학회마을
DOI
|
32 |
Vardy J, Chiew KS, Galica J, et al (2006). Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer, 94, 1011-5.
DOI
|
33 |
Wang XF, Feng Y, Chen Y, Gao BL, Han BH (2014). A metaanalysis of olanzapine for the prevention of chemotherapyinduced nausea and vomiting. Sci Rep, 4, 4813.
|
34 |
Vig S, Seibert L, Green MR (2014). Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity. J Cancer Res Clin Oncol, 140, 77-82.
DOI
|
35 |
Welti J, Loges S, Dimmeler S, et al (2013). Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest, 123, 3190-200.
DOI
|
36 |
Wang SY, He Y, Zhang L, et al (2014). The effects of olanzapine, tropisetron and dexamethasone to preventing the nausea and vomiting induced by multi-day highly or moderately emetogenic chemotherapy in cancer patients. Chinese clinical oncology, CSCO, 544-5.
|
37 |
Yuan Lingyan, Jiao Xiaodong, Wang Zhan, et al (2013). Olanzapine combined granisetron and dexamethasone for the prevention of chemotherapy-induced emesis and nausea in cancer patients: A phase I trial. Chinese Clin Oncol, 18, 511-4.
|